Cellectar Accounts Payable from 2010 to 2025

CLRB Stock  USD 0.31  0.02  6.06%   
Cellectar Biosciences' Accounts Payable is increasing over the years with slightly volatile fluctuation. Overall, Accounts Payable is expected to go to about 6.8 M this year. Accounts Payable is the amount Cellectar Biosciences owes to suppliers or vendors for products or services received but not yet paid for. It represents Cellectar Biosciences' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2005-03-31
Previous Quarter
5.6 M
Current Value
6.5 M
Quarterly Volatility
2.4 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cellectar Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cellectar Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 285 K, Interest Expense of 363.4 K or Selling General Administrative of 13 M, as well as many indicators such as Dividend Yield of 0.46, Days Sales Outstanding of 741 or Invested Capital of 0.0. Cellectar financial statements analysis is a perfect complement when working with Cellectar Biosciences Valuation or Volatility modules.
  
Check out the analysis of Cellectar Biosciences Correlation against competitors.
For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.

Latest Cellectar Biosciences' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of Cellectar Biosciences over the last few years. An accounting item on the balance sheet that represents Cellectar Biosciences obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Cellectar Biosciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. Cellectar Biosciences' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cellectar Biosciences' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
1.3M1.4M1.4M2.6M5.6M6.5M6.8M12%-1%81%120%15%5%100%
       Timeline  

Cellectar Accounts Payable Regression Statistics

Arithmetic Mean1,928,388
Geometric Mean360,698
Coefficient Of Variation118.85
Mean Deviation1,714,200
Median1,415,000
Standard Deviation2,291,801
Sample Variance5.3T
Range6.8M
R-Value0.82
Mean Square Error1.8T
R-Squared0.67
Significance0.000097
Slope395,208
Total Sum of Squares78.8T

Cellectar Accounts Payable History

20256.8 M
20246.5 M
20235.6 M
20222.6 M
20211.4 M
20201.4 M
20191.3 M

About Cellectar Biosciences Financial Statements

Cellectar Biosciences stakeholders use historical fundamental indicators, such as Cellectar Biosciences' Accounts Payable, to determine how well the company is positioned to perform in the future. Although Cellectar Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cellectar Biosciences' assets and liabilities are reflected in the revenues and expenses on Cellectar Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cellectar Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Accounts Payable6.5 M6.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Cellectar Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cellectar Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cellectar Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cellectar Biosciences Stock:
Check out the analysis of Cellectar Biosciences Correlation against competitors.
For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. If investors know Cellectar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectar Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.41)
Return On Assets
(1.10)
Return On Equity
(4.75)
The market value of Cellectar Biosciences is measured differently than its book value, which is the value of Cellectar that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectar Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cellectar Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectar Biosciences' market value can be influenced by many factors that don't directly affect Cellectar Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cellectar Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectar Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectar Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
News Freq…Investor S…